Equities researchers at StockNews.com assumed coverage on shares of Verastem (NASDAQ:VSTM – Get Rating) in a research note issued to investors on Monday. The firm set a “hold” rating on the biopharmaceutical company’s stock.
A number of other equities research analysts have also issued reports on VSTM. HC Wainwright dropped their price target on Verastem from $5.00 to $3.00 and set a “buy” rating for the company in a research report on Monday, November 7th. BTIG Research dropped their price target on Verastem from $8.00 to $5.00 and set a “buy” rating for the company in a research report on Wednesday, October 5th. Finally, Alliance Global Partners restated a “buy” rating and issued a $6.00 price target on shares of Verastem in a research report on Wednesday, September 7th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, Verastem currently has a consensus rating of “Moderate Buy” and an average price target of $5.00.
Verastem Price Performance
NASDAQ:VSTM opened at $0.41 on Monday. Verastem has a 12 month low of $0.29 and a 12 month high of $3.02. The stock has a 50 day moving average of $0.61 and a two-hundred day moving average of $0.99. The company has a current ratio of 4.97, a quick ratio of 4.97 and a debt-to-equity ratio of 0.39. The firm has a market cap of $85.70 million, a P/E ratio of -1.05 and a beta of 0.62.
Institutional Inflows and Outflows
Verastem, Inc, a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK.
- Get a free copy of the StockNews.com research report on Verastem (VSTM)
- Here’s Why SoFi Technologies Stock is Cheap at These Levels
- Warren Buffet Bought Taiwan Semiconductor Stock, Should You?
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.